Curated News
By: NewsRamp Editorial Staff
April 20, 2026
Helus Pharma Applauds White House Push for Psychedelic Treatments
TLDR
- Helus Pharma's Phase 3 HLP003 program with Breakthrough Therapy designation positions the company to gain a competitive edge in the emerging psychedelic treatment market.
- The White House Executive Order aims to accelerate research, regulatory pathways, and patient access to psychedelic treatments through FDA prioritization and interagency coordination.
- This initiative could improve mental health treatment by expanding access to psychedelic therapies, potentially helping millions suffering from depression and anxiety.
- Helus Pharma is developing synthetic molecules called NSAs designed to activate serotonin pathways and promote neuroplasticity for treating mental health conditions.
Impact - Why it Matters
This news matters because it signals a major shift in federal policy that could dramatically accelerate the availability of new mental health treatments. The White House Executive Order represents a significant governmental endorsement of psychedelic-assisted therapies, potentially streamlining the FDA review process and increasing funding for research. For the millions suffering from treatment-resistant depression and anxiety, this could mean faster access to potentially life-changing medications like Helus Pharma's HLP003. The company's Breakthrough Therapy designation already indicates the therapy's promise, and this executive action could help bring it to patients sooner. Furthermore, it validates the entire emerging psychedelic medicine sector, potentially attracting more investment and research into novel treatments for the global mental health crisis.
Summary
Helus Pharma™, the commercial operating name of Cybin Inc., has enthusiastically welcomed a White House Executive Order that aims to accelerate research, regulatory pathways, and patient access to psychedelic treatments. The company, which trades on NASDAQ as HELP and on the Cboe CA as HELP, sees this initiative as a potential catalyst to prioritize FDA review, expand patient access, and strengthen interagency coordination. This development is particularly significant for Helus Pharma, as it aligns with the company's own advanced clinical programs, most notably its Phase 3 HLP003 program for major depressive disorder, which has already received the coveted Breakthrough Therapy designation from the U.S. Food and Drug Administration.
The core of Helus Pharma's mission is to develop proprietary Novel Serotonergic Agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's flagship product, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder, while HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma emphasizes that continued progress in the psychedelic treatment field hinges on strong clinical evidence and the development of scalable, safe treatments. The company operates in Canada, the United States, the United Kingdom, and Ireland, and for more information, you can visit their website or follow them on social media platforms.
This news was disseminated by the PsychedelicNewsWire, a specialized communications platform within the Dynamic Brand Portfolio of the InvestorBrandNetwork (IBN). The platform focuses on all aspects of psychedelics and provides extensive distribution services, including access to a vast network of wire solutions via InvestorWire, article syndication to over 5,000 outlets, and enhanced press release services. For the latest updates relating to HELP, investors are directed to the company's newsroom. The full press release can be viewed for more detailed information on this significant regulatory and corporate development.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Applauds White House Push for Psychedelic Treatments
